Eli Lilly Gets US FDA Nod For Once-Weekly Onswik Insulin For Type 2 Diabetes
NDTV Profit · 24 September 2026

Lilly’s FDA approval is based on the QWINT Phase 3 programme, which evaluated Onswik in more than 3,400 adults with type 2 diabetes across four clinical trials.
Full story published by NDTV Profit. Namaste Indian aggregates India headlines so you can discover and discuss them with people across every state.
Related articles
- PMS Overhaul: SEBI Allows IPO Bets, Investments In Foreign Securities; Eases Compliance Norms
NDTV Profit
- Vir Das, Real Kashmir Football Club Earn International Emmy 2026 Nominations
NDTV Profit
- Chinese CEOs await invites to Trump-Xi state dinner
Firstpost
- NSE lists at a modest premium of 0.8%
The Hindu
- Europe's Gas Security Depends On Asian Demand | The Reason Why
NDTV Profit
- RBI Deputy Governor Rohit Jain Expects To Deploy Additional Liquidity Over Coming Months, Amid Consolidated Credit Demand
NDTV Profit